() News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1152948,
    "name": "Cytokinetics, Inc.",
    "stock_name": "Cytokinetics, Inc.",
    "full_name": "Cytokinetics, Inc.",
    "name_url": "stocks-analysis/cytokinetics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "66.54",
    "chg": 3.03,
    "chgp": "4.77%",
    "dir": 1,
    "prev_price": "63.51",
    "mcapval": "6,232.94",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US23282W6057",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "3.04 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cytokinetics-inc-1152948-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Cytokinetics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cytokinetics-inc-technically-bullish-or-bearish-3673568",
        "imagepath": "",
        "date": "2025-11-05 11:19:50",
        "description": "As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The weekly MACD and daily moving averages indicate a bullish stance, while the weekly RSI is bearish, suggesting some divergence in momentum. The Bollinger Bands are mildly bullish on both weekly and monthly time frames. The KST shows bullish momentum weekly but is bearish monthly, indicating mixed signals. Overall, the technical stance is bullish but with some caution due to the bearish RSI. \n\nIn terms of performance, Cytokinetics has outperformed the S&P 500 year-to-date with a return of 26.74% compared to 16.30%, but it lags over the 1-year and 3-year periods...."
      },
      {
        "title": "Cytokinetics, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytokinetics-inc-technical-trend-changes-from-mildly-bullish-to-bullish-amid-stock-volatility-3671371",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/CytokineticsInc_technicaldot_3671371.png",
        "date": "2025-11-04 15:39:40",
        "description": "Cytokinetics, Inc. has recently revised its evaluation amid changing market conditions. The company's stock is priced at $60.03, with a notable 15.84% return over the past year. Over five years, it has achieved a remarkable 259.03% return, showcasing its resilience in the competitive pharmaceuticals sector."
      },
      {
        "title": "Is Cytokinetics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cytokinetics-inc-technically-bullish-or-bearish-3670760",
        "imagepath": "",
        "date": "2025-11-04 11:31:22",
        "description": "As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong emphasis on weekly and monthly MACD indicators, both of which are bullish. Additionally, Bollinger Bands are bullish on both time frames, and daily moving averages also indicate a bullish trend. However, the weekly RSI is bearish, which introduces some caution. Dow Theory and OBV show a mildly bullish stance on both weekly and monthly charts. \n\nIn terms of performance, the stock has returned 27.61% year-to-date, significantly outperforming the S&P 500's 16.30%, but underperformed over the 1-year period with a return of 15.84% compared to the S&P 500's 19.89%. Overall, the technical indicators suggest a bullish outlook, albeit with some mixed signals in the RSI...."
      },
      {
        "title": "Is Cytokinetics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cytokinetics-inc-technically-bullish-or-bearish-3666353",
        "imagepath": "",
        "date": "2025-11-03 11:30:26",
        "description": "As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The weekly MACD and Bollinger Bands are both bullish, supporting the positive trend. However, the weekly RSI is bearish, indicating some short-term weakness. The daily moving averages are bullish, reinforcing the overall positive stance. Dow Theory and OBV are both mildly bullish on a weekly and monthly basis. \n\nCytokinetics has outperformed the S&P 500 across multiple periods, with a year-to-date return of 35.18% compared to the S&P 500's 16.30%, and a 5-year return of 313.73% versus 109.18% for the benchmark. Overall, the current technical stance is bullish, with moderate strength driven by the positive MACD and moving averages...."
      },
      {
        "title": "Is Cytokinetics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-cytokinetics-inc-technically-bullish-or-bearish-3664467",
        "imagepath": "",
        "date": "2025-11-02 11:16:21",
        "description": "As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the weekly and monthly MACD, Bollinger Bands, and daily moving averages. However, the weekly RSI is bearish, indicating some short-term weakness. The KST shows a bullish weekly trend but is bearish monthly, while Dow Theory and OBV are both mildly bullish on a weekly and monthly basis. \n\nCytokinetics has outperformed the S&P 500 across multiple periods, with a year-to-date return of 35.18% compared to the S&P 500's 16.30%, and a five-year return of 313.73% versus 109.18% for the index...."
      },
      {
        "title": "Cytokinetics, Inc. Hits New 52-Week High at USD 64.13",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytokinetics-inc-hits-new-52-week-high-at-usd-6413-3661928",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CytokineticsInc_priceRelatedfactors_3661928.png",
        "date": "2025-10-31 16:10:26",
        "description": "Cytokinetics, Inc. has achieved a new 52-week high of USD 64.13, significantly up from its low of USD 29.31. The company, with a market cap of USD 6,233 million, shows a 14.94% performance increase over the past year and maintains a low debt-to-equity ratio and high return on equity."
      },
      {
        "title": "Cytokinetics, Inc. Experiences Revision in Stock Evaluation Amidst Market Fluctuations",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytokinetics-inc-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-strong-performance-3640383",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CytokineticsInc_technicaldot_3640383.png",
        "date": "2025-10-20 15:14:45",
        "description": "Cytokinetics, Inc. has experienced notable stock fluctuations, with a current price of $58.44. The company has shown resilience, achieving a 22.88% return over the past month and a 24.23% year-to-date return, significantly outperforming the S&P 500. Its five-year return stands at 254.83%."
      },
      {
        "title": "Cytokinetics, Inc. Hits New 52-Week High at $63.86",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytokinetics-inc-hits-new-52-week-high-at-6386-3626608",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CytokineticsInc_priceRelatedfactors_3626608.png",
        "date": "2025-10-16 18:15:11",
        "description": "Cytokinetics, Inc. achieved a new 52-week high of USD 63.86 on October 15, 2025, reflecting a strong performance over the past year. With a market capitalization of USD 6,233 million, the company demonstrates solid financial health, including a low debt-to-equity ratio and a high return on equity."
      },
      {
        "title": "Cytokinetics, Inc. Hits New 52-Week High at $61.58",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cytokinetics-inc-hits-new-52-week-high-at-6158-3622773",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/CytokineticsInc_priceRelatedfactors_3622773.png",
        "date": "2025-10-15 16:53:05",
        "description": "Cytokinetics, Inc. has achieved a new 52-week high, reflecting strong performance over the past year. The company, with a market capitalization of USD 6,233 million, shows impressive financial metrics, including a high return on equity. It maintains a low debt-to-equity ratio and does not offer dividends."
      }
    ],
    "total": 23,
    "sid": "1152948",
    "stock_news_url": "https://www.marketsmojo.com/news/No announcements on  in the last one month-1152948"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Cytokinetics, Inc. technically bullish or bearish?

2025-11-05 11:19:50

As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The weekly MACD and daily moving averages indicate a bullish stance, while the weekly RSI is bearish, suggesting some divergence in momentum. The Bollinger Bands are mildly bullish on both weekly and monthly time frames. The KST shows bullish momentum weekly but is bearish monthly, indicating mixed signals. Overall, the technical stance is bullish but with some caution due to the bearish RSI. In terms of performance, Cytokinetics has outperformed the S&P 500 year-to-date with a return of 26.74% compared to 16.30%, but it lags over the 1-year and 3-year periods....

Cytokinetics, Inc. Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators

2025-11-04 15:39:40

Cytokinetics, Inc. has recently revised its evaluation amid changing market conditions. The company's stock is priced at $60.03, with a notable 15.84% return over the past year. Over five years, it has achieved a remarkable 259.03% return, showcasing its resilience in the competitive pharmaceuticals sector.

Is Cytokinetics, Inc. technically bullish or bearish?

2025-11-04 11:31:22

As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with a strong emphasis on weekly and monthly MACD indicators, both of which are bullish. Additionally, Bollinger Bands are bullish on both time frames, and daily moving averages also indicate a bullish trend. However, the weekly RSI is bearish, which introduces some caution. Dow Theory and OBV show a mildly bullish stance on both weekly and monthly charts. In terms of performance, the stock has returned 27.61% year-to-date, significantly outperforming the S&P 500's 16.30%, but underperformed over the 1-year period with a return of 15.84% compared to the S&P 500's 19.89%. Overall, the technical indicators suggest a bullish outlook, albeit with some mixed signals in the RSI....

Is Cytokinetics, Inc. technically bullish or bearish?

2025-11-03 11:30:26

As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The weekly MACD and Bollinger Bands are both bullish, supporting the positive trend. However, the weekly RSI is bearish, indicating some short-term weakness. The daily moving averages are bullish, reinforcing the overall positive stance. Dow Theory and OBV are both mildly bullish on a weekly and monthly basis. Cytokinetics has outperformed the S&P 500 across multiple periods, with a year-to-date return of 35.18% compared to the S&P 500's 16.30%, and a 5-year return of 313.73% versus 109.18% for the benchmark. Overall, the current technical stance is bullish, with moderate strength driven by the positive MACD and moving averages....

Is Cytokinetics, Inc. technically bullish or bearish?

2025-11-02 11:16:21

As of 31 October 2025, the technical trend for Cytokinetics, Inc. has changed from mildly bullish to bullish. The current stance is bullish, supported by bullish signals in the weekly and monthly MACD, Bollinger Bands, and daily moving averages. However, the weekly RSI is bearish, indicating some short-term weakness. The KST shows a bullish weekly trend but is bearish monthly, while Dow Theory and OBV are both mildly bullish on a weekly and monthly basis. Cytokinetics has outperformed the S&P 500 across multiple periods, with a year-to-date return of 35.18% compared to the S&P 500's 16.30%, and a five-year return of 313.73% versus 109.18% for the index....

Cytokinetics, Inc. Hits New 52-Week High at USD 64.13

2025-10-31 16:10:26

Cytokinetics, Inc. has achieved a new 52-week high of USD 64.13, significantly up from its low of USD 29.31. The company, with a market cap of USD 6,233 million, shows a 14.94% performance increase over the past year and maintains a low debt-to-equity ratio and high return on equity.

Cytokinetics, Inc. Experiences Revision in Stock Evaluation Amidst Market Fluctuations

2025-10-20 15:14:45

Cytokinetics, Inc. has experienced notable stock fluctuations, with a current price of $58.44. The company has shown resilience, achieving a 22.88% return over the past month and a 24.23% year-to-date return, significantly outperforming the S&P 500. Its five-year return stands at 254.83%.

Cytokinetics, Inc. Hits New 52-Week High at $63.86

2025-10-16 18:15:11

Cytokinetics, Inc. achieved a new 52-week high of USD 63.86 on October 15, 2025, reflecting a strong performance over the past year. With a market capitalization of USD 6,233 million, the company demonstrates solid financial health, including a low debt-to-equity ratio and a high return on equity.

Cytokinetics, Inc. Hits New 52-Week High at $61.58

2025-10-15 16:53:05

Cytokinetics, Inc. has achieved a new 52-week high, reflecting strong performance over the past year. The company, with a market capitalization of USD 6,233 million, shows impressive financial metrics, including a high return on equity. It maintains a low debt-to-equity ratio and does not offer dividends.

View All News